CN106068263A - 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 - Google Patents
用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 Download PDFInfo
- Publication number
- CN106068263A CN106068263A CN201580009889.2A CN201580009889A CN106068263A CN 106068263 A CN106068263 A CN 106068263A CN 201580009889 A CN201580009889 A CN 201580009889A CN 106068263 A CN106068263 A CN 106068263A
- Authority
- CN
- China
- Prior art keywords
- unsubstituted
- substituted
- cancer
- compound
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*c1ccc(C(*)*O)c(*)c1 Chemical compound C*c1ccc(C(*)*O)c(*)c1 0.000 description 11
- FZSDRBCGFKGDET-UHFFFAOYSA-N Bc1cccc(Br)c1 Chemical compound Bc1cccc(Br)c1 FZSDRBCGFKGDET-UHFFFAOYSA-N 0.000 description 1
- PILBYRUFBVDOSH-UHFFFAOYSA-N Brc1cccc(NC2CC2)c1 Chemical compound Brc1cccc(NC2CC2)c1 PILBYRUFBVDOSH-UHFFFAOYSA-N 0.000 description 1
- MXHGRDSXPIVMTH-UHFFFAOYSA-N CC(CC1)CCC1C(C1)=CC(Br)=CC1I Chemical compound CC(CC1)CCC1C(C1)=CC(Br)=CC1I MXHGRDSXPIVMTH-UHFFFAOYSA-N 0.000 description 1
- MQFQAFPUIQMHSN-UHFFFAOYSA-N IC(CC1CC1)N1CC1 Chemical compound IC(CC1CC1)N1CC1 MQFQAFPUIQMHSN-UHFFFAOYSA-N 0.000 description 1
- ZIDZSXPCVIJYJR-UHFFFAOYSA-N Ic1cccc(C2CC2)c1 Chemical compound Ic1cccc(C2CC2)c1 ZIDZSXPCVIJYJR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210190090.XA CN114634483B (zh) | 2014-02-21 | 2015-02-20 | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461942956P | 2014-02-21 | 2014-02-21 | |
| US61/942,956 | 2014-02-21 | ||
| PCT/US2015/016928 WO2015127284A2 (en) | 2014-02-21 | 2015-02-20 | Antimitotic amides for the treatment of cancer and proliferative disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210190090.XA Division CN114634483B (zh) | 2014-02-21 | 2015-02-20 | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106068263A true CN106068263A (zh) | 2016-11-02 |
Family
ID=52684675
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210190090.XA Active CN114634483B (zh) | 2014-02-21 | 2015-02-20 | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 |
| CN201580009889.2A Pending CN106068263A (zh) | 2014-02-21 | 2015-02-20 | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210190090.XA Active CN114634483B (zh) | 2014-02-21 | 2015-02-20 | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10016398B2 (enExample) |
| EP (1) | EP3107909B1 (enExample) |
| JP (1) | JP6506313B2 (enExample) |
| KR (1) | KR102420508B1 (enExample) |
| CN (2) | CN114634483B (enExample) |
| AU (1) | AU2015218775C1 (enExample) |
| BR (1) | BR112016019161B1 (enExample) |
| CA (1) | CA2940237C (enExample) |
| ES (1) | ES2893374T3 (enExample) |
| IL (1) | IL247293B (enExample) |
| MX (1) | MX390530B (enExample) |
| RU (1) | RU2713179C2 (enExample) |
| SG (2) | SG10202000590SA (enExample) |
| WO (1) | WO2015127284A2 (enExample) |
| ZA (1) | ZA201606471B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727583A (zh) * | 2016-12-12 | 2017-05-31 | 范旭升 | 一种治疗舒张性心衰的药物组合物 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| JP6506313B2 (ja) * | 2014-02-21 | 2019-04-24 | フロスト バイオロジック，インコーポレーテッド | 癌及び増殖性疾患の治療のための抗有糸分裂性アミド |
| US11377436B2 (en) * | 2017-07-12 | 2022-07-05 | The Brigham And Women's Hospital, Inc. | EAAT2 enhancing molecules |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| WO2025248483A1 (ko) * | 2024-05-30 | 2025-12-04 | 삼진제약주식회사 | Nr2f6 억제제 및 이의 용도 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1433413A (zh) * | 2000-06-05 | 2003-07-30 | 东亚制药株式会社 | 新的噁唑烷酮衍生物及其制备方法 |
| WO2010100475A1 (en) * | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| US20110263612A1 (en) * | 2010-04-27 | 2011-10-27 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2012107475A1 (en) * | 2011-02-10 | 2012-08-16 | Syngenta Participations Ag | Microbiocidal pyrazole derivatives |
| WO2013063385A1 (en) * | 2011-10-28 | 2013-05-02 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| MXPA06015106A (es) * | 2004-06-30 | 2007-02-08 | Novartis Ag | Metodo para aumentar la susceptibilidad de los inhibidores de la peptidil-desformilasa mediante la utilizacion de inhibidores de la bomba de eflujo. |
| US20090156646A1 (en) * | 2005-08-11 | 2009-06-18 | Takeda Pharmaceutical Company Limited | Pyridylphenol compound and use thereof |
| PL1984338T3 (pl) * | 2006-01-31 | 2013-06-28 | Synta Pharmaceuticals Corp | Związki pirydylofenylowe do zastosowań związanych z zapaleniami i odpornością |
| JP2010510191A (ja) | 2006-11-17 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | 抗ウイルス剤としての２−カルボキシチオフェン誘導体 |
| DE602008004650D1 (de) * | 2007-04-12 | 2011-03-03 | Hoffmann La Roche | Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase |
| US20110118281A9 (en) * | 2008-10-01 | 2011-05-19 | Gary Bohnert | Compounds for inflammation and immune-related uses |
| ES2528485T3 (es) * | 2009-09-11 | 2015-02-10 | Amgen, Inc | N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina para su uso en el tratamiento del cáncer resistente a agentes antimitóticos |
| US20130063385A1 (en) * | 2010-05-14 | 2013-03-14 | Sharp Kabushiki Kaisha | Portable information terminal and method for controlling same |
| TWI541243B (zh) * | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| JP2014503000A (ja) * | 2011-01-21 | 2014-02-06 | アッヴィ・インコーポレイテッド | キナーゼのピコリンアミド阻害剤 |
| JP5985611B2 (ja) * | 2011-05-03 | 2016-09-06 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途のための化合物 |
| JP6506313B2 (ja) * | 2014-02-21 | 2019-04-24 | フロスト バイオロジック，インコーポレーテッド | 癌及び増殖性疾患の治療のための抗有糸分裂性アミド |
-
2015
- 2015-02-20 JP JP2016570919A patent/JP6506313B2/ja active Active
- 2015-02-20 SG SG10202000590SA patent/SG10202000590SA/en unknown
- 2015-02-20 WO PCT/US2015/016928 patent/WO2015127284A2/en not_active Ceased
- 2015-02-20 MX MX2016010877A patent/MX390530B/es unknown
- 2015-02-20 CN CN202210190090.XA patent/CN114634483B/zh active Active
- 2015-02-20 RU RU2016135555A patent/RU2713179C2/ru active
- 2015-02-20 CA CA2940237A patent/CA2940237C/en active Active
- 2015-02-20 KR KR1020167026016A patent/KR102420508B1/ko active Active
- 2015-02-20 CN CN201580009889.2A patent/CN106068263A/zh active Pending
- 2015-02-20 ES ES15710328T patent/ES2893374T3/es active Active
- 2015-02-20 SG SG11201606869TA patent/SG11201606869TA/en unknown
- 2015-02-20 AU AU2015218775A patent/AU2015218775C1/en active Active
- 2015-02-20 US US15/120,470 patent/US10016398B2/en active Active
- 2015-02-20 BR BR112016019161-7A patent/BR112016019161B1/pt active IP Right Grant
- 2015-02-20 EP EP15710328.4A patent/EP3107909B1/en active Active
-
2016
- 2016-08-16 IL IL247293A patent/IL247293B/en active IP Right Grant
- 2016-09-20 ZA ZA2016/06471A patent/ZA201606471B/en unknown
-
2018
- 2018-06-29 US US16/024,407 patent/US10772872B2/en active Active
-
2020
- 2020-09-03 US US17/011,589 patent/US11129813B2/en active Active
-
2021
- 2021-09-13 US US17/473,364 patent/US12383533B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1433413A (zh) * | 2000-06-05 | 2003-07-30 | 东亚制药株式会社 | 新的噁唑烷酮衍生物及其制备方法 |
| WO2010100475A1 (en) * | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| US20110263612A1 (en) * | 2010-04-27 | 2011-10-27 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2012107475A1 (en) * | 2011-02-10 | 2012-08-16 | Syngenta Participations Ag | Microbiocidal pyrazole derivatives |
| WO2013063385A1 (en) * | 2011-10-28 | 2013-05-02 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727583A (zh) * | 2016-12-12 | 2017-05-31 | 范旭升 | 一种治疗舒张性心衰的药物组合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105324117B (zh) | 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物 | |
| CN115322158B (zh) | 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物 | |
| CN114634483B (zh) | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 | |
| CN105555785B (zh) | 作为dyrk激酶抑制剂的2，3-二氢苯并呋喃-5-基化合物 | |
| CN115916754A (zh) | 杂芳族大环醚化学治疗剂 | |
| WO2017084494A1 (zh) | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 | |
| WO2016026445A1 (zh) | 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用 | |
| AU2016262642A1 (en) | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds | |
| CN110407839A (zh) | 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用 | |
| CN104974109A (zh) | 含噻唑的丙炔酰胺类衍生物及其制法和药物组合物与用途 | |
| CN104109121B (zh) | N′-芳乙酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途 | |
| KR101920163B1 (ko) | 항암용 약학 조성물 | |
| CN104974104B (zh) | 含噁唑的丙炔酰胺类衍生物及其制法和药物组合物与用途 | |
| CN113493414A (zh) | 一种氘代取代丁烯酰胺及其制备方法与应用 | |
| CN103570616B (zh) | N′‑直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途 | |
| CN104109120B (zh) | N′-芳丙烯酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途 | |
| HK1232858B (en) | Antimitotic amides for the treatment of cancer and proliferative disorders | |
| CN119241539A (zh) | 含吡唑并哌啶（酮）衍生物及其制备方法和应用 | |
| WO2025198588A1 (en) | Preparation of compound and crystalline forms thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161102 |